Skip to main content

A randomized, double-blind, placebo-controlled, parallelgroup,Proof-of-Concept (PoC) study to assess theefficacy,safety and tolerability of itepekimab in participants with non-cystic fibrosis bronchiectasis

Open
  • Protocol code: ACT18018
  • EudraCT code: No aplica
  • Research group: Pneumology
  • Service: Pneumology
  • Principal investigator:  Polverino , Eva
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase I